Teva rare disease drug "thorium-deprenazine tablets" on the domestic report

On December 27th, Teva's Deutetrabenanazine was approved by the Drug Ethos Center (CDE) for the treatment of the rare autosomal dominant genetic disease, Huntington's diseaseDeutetrabenazine, developed by Teva, is a cystic monoamine transporter 2 (VMAT2) inhibitorFda approved for the treatment of Huntington's disease in 2017, becoming the first drug to be marketed in historythyphaebenzene is a derivative of Tetrabenazine, in which six H (hydrogen atoms) of two methicillin sylactants in the benzene ring are replaced by D (thorium atom), the doping of radon reduces the rate of drug metabolism, reduces the frequency of administration, and significantly improves the safety and effectiveness of the drugHuntington's disease is a rare autosomal dominant genetic disease that currently has no effective treatmentClinical studies have shown that the use of thorium-deprecativebenzene in the treatment of Huntington's disease has a clear effectin China, the species was included in the first batch of clinically urgent lying new drugs published by the state in November 2018;the following image from insight database - clinically urgent need of new drugs abroad (https://db.dxy.cn)original title: Rare disease drug "Thybinbena" domestic newspaper, treatment of Huntington's disease